Tessera Ther­a­peu­tics taps for­mer BeiGene CFO Howard Liang to join race to CRISPR 3.0

A day af­ter Prime Med­i­cines emerged from se­mi-stealth with new CRISPR tech that made even ven­ture cap­i­tal­ist Bob Nelsen say “holy crap,” a Cam­bridge, MA-based com­pa­ny with sim­i­lar am­bi­tions in the works is beef­ing up its ex­ec­u­tive suite — start­ing with for­mer BeiGene CFO Howard Liang.

Tessera Ther­a­peu­tics has tapped Liang as its first CFO, in ad­di­tion to sev­er­al oth­er new hires in­clud­ing Mana Ther­a­peu­tics vet Mad­husu­dan Pesh­wa as CTO for cell ther­a­py; Avro­bio alum Bill Querbes as se­nior VP of ther­a­peu­tic dis­cov­ery and trans­la­tion­al sci­ences; and in­sitro’s for­mer head of func­tion­al ge­nomics Ce­cil­ia Cot­ta-Ra­musi­no as se­nior VP of plat­form de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER